DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday

DiaMedica Therapeutics (NASDAQ:DMAC) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.17) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:00 PM ET.

DiaMedica Therapeutics Stock Up 1.6%

DiaMedica Therapeutics stock opened at $7.71 on Monday. The business has a 50 day moving average price of $8.21 and a two-hundred day moving average price of $7.54. DiaMedica Therapeutics has a 12 month low of $3.19 and a 12 month high of $10.42. The stock has a market cap of $401.54 million, a price-to-earnings ratio of -10.86 and a beta of 1.09.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Cantor Fitzgerald assumed coverage on DiaMedica Therapeutics in a research report on Friday, November 14th. They set an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, January 21st. Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. Finally, Wall Street Zen lowered shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.33.

Institutional Investors Weigh In On DiaMedica Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. raised its holdings in shares of DiaMedica Therapeutics by 131.5% in the 3rd quarter. Raymond James Financial Inc. now owns 36,501 shares of the company’s stock worth $251,000 after buying an additional 20,734 shares in the last quarter. Trexquant Investment LP acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at $246,000. Marshall Wace LLP grew its position in DiaMedica Therapeutics by 227.8% in the second quarter. Marshall Wace LLP now owns 61,719 shares of the company’s stock valued at $241,000 after acquiring an additional 42,890 shares during the period. XTX Topco Ltd bought a new stake in DiaMedica Therapeutics in the fourth quarter valued at $234,000. Finally, Quadrature Capital Ltd acquired a new position in DiaMedica Therapeutics during the fourth quarter worth $188,000. 10.12% of the stock is owned by institutional investors and hedge funds.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.